BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Surasak Jittavisutthikul, Jeeraphong Thanongsaksrikul, Kanyarat Thueng-in, Monrat Chulanetra, Potjanee Srimanote, Watee Seesuay, Aijaz Malik, Wanpen Chaicumpa. Humanized-VHH Transbodies that Inhibit HCV Protease and ReplicationViruses 2015; 7(4): 2030 doi: 10.3390/v7042030
2
Tatsuo Kanda, Kazushige Nirei, Naoki Matsumoto, Teruhisa Higuchi, Hitomi Nakamura, Hiroaki Yamagami, Shunichi Matsuoka, Mitsuhiko Moriyama. Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1bWorld Journal of Gastroenterology 2017; 23(46): 8120-8127 doi: 10.3748/wjg.v23.i46.8120
3
Hubert G. M. Niesters, Annelies Riezebos-Brilman, Coretta C. Van Leer-Buter. Manual of Molecular and Clinical Laboratory Immunology2016; : 620 doi: 10.1128/9781555818722.ch65
4
Andrea Magri, Alexander A. Ozerov, Vera L. Tunitskaya, Vladimir T. Valuev-Elliston, Ahmed Wahid, Mario Pirisi, Peter Simmonds, Alexander V. Ivanov, Mikhail S. Novikov, Arvind H. Patel. Exploration of acetanilide derivatives of 1-(ω-phenoxyalkyl)uracils as novel inhibitors of Hepatitis C Virus replicationScientific Reports 2016; 6(1) doi: 10.1038/srep29487
5
Midori Kjellin, Terése Wesslén, Erik Löfblad, Johan Lennerstrand, Anders Lannergård. The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohortUpsala Journal of Medical Sciences 2018; 123(1): 50 doi: 10.1080/03009734.2018.1441928
6
Betsaida Bibo-Verdugo, Zhenze Jiang, Conor R. Caffrey, Anthony J. O'Donoghue. Targeting proteasomes in infectious organisms to combat diseaseThe FEBS Journal 2017; 284(10): 1503 doi: 10.1111/febs.14029
7
Aravindhan Ganesan, Khaled Barakat. Applications of computer-aided approaches in the development of hepatitis C antiviral agentsExpert Opinion on Drug Discovery 2017; 12(4): 407 doi: 10.1080/17460441.2017.1291628
8
Tatsuo Kanda, Osamu Yokosuka, Masao Omata. Faldaprevir for the Treatment of Hepatitis CInternational Journal of Molecular Sciences 2015; 16(12): 4985 doi: 10.3390/ijms16034985
9
Lize Cuypers, Francesca Ceccherini-Silberstein, Kristel Van Laethem, Guangdi Li, Anne-Mieke Vandamme, Jürgen Kurt Rockstroh. Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in timeReviews in Medical Virology 2016; 26(6): 408 doi: 10.1002/rmv.1895
10
Kittirat Glab-ampai, Monrat Chulanetra, Aijaz Ahmad Malik, Thanate Juntadech, Jeeraphong Thanongsaksrikul, Potjanee Srimanote, Kanyarat Thueng-in, Nitat Sookrung, Pongsri Tongtawe, Wanpen Chaicumpa. Human single chain-transbodies that bound to domain-I of non-structural protein 5A (NS5A) of hepatitis C virusScientific Reports 2017; 7(1) doi: 10.1038/s41598-017-14886-9
11
Aqsa Ikram, Ayesha Obaid, Faryal Mehwish Awan, Rumeza Hanif, Anam Naz, Rehan Zafar Paracha, Amjad Ali, Hussnain Ahmed Janjua. Identification of drug resistance and immune-driven variations in hepatitis C virus (HCV) NS3/4A, NS5A and NS5B regions reveals a new approach toward personalized medicineAntiviral Research 2017; 137: 112 doi: 10.1016/j.antiviral.2016.10.013
12
Navaneethan Palanisamy, Johan Lennerstrand. Biophysical Studies on HCV 1a NS3/4A Protease and Its Catalytic Triad in Wild Type and Mutants by the In Silico ApproachInterdisciplinary Sciences: Computational Life Sciences 2018; 10(1): 143 doi: 10.1007/s12539-016-0177-4
13
Ying Cao, Yi Bao, Wei Xia, Hao Wu, Feili Wei, Yu Zhang, Renwen Zhang, Xiaoyuan Xu. Resistance-associated mutations to HCV protease inhibitors naturally pre-existed in HIV/HCV coinfected, treatment-naïve patientsClinics and Research in Hepatology and Gastroenterology 2016; 40(5): 597 doi: 10.1016/j.clinre.2016.02.004
14
Luísa Hoffmann, Débora Souza Faffe, Jennifer Fróes Cruz Lima, Thayanna Araujo Capitanio, Bianca Catarina Azeredo Cabral, Turán Péter Ürményi, Henrique Sergio Moraes Coelho, Edson Rondinelli, Cristiane Alves Villela-Nogueira, Rosane Silva. No correspondence between resistance mutations in the HCV-NS3 protease at baseline and early telaprevir-based triple therapyBBA Clinical 2015; 3: 146 doi: 10.1016/j.bbacli.2015.01.004
15
Thitiya Boonma, Bodee Nutho, Thanyada Rungrotmongkol, Nadtanet Nunthaboot. Understanding of the drug resistance mechanism of hepatitis C virus NS3/4A to paritaprevir due to D168N/Y mutations: A molecular dynamics simulation perspectiveComputational Biology and Chemistry 2019; 83: 107154 doi: 10.1016/j.compbiolchem.2019.107154
16
Tatsuya Aikawa, Chisato Ueno, Yohko Kikuchi, Fumio Tsuda, Hiroshi Ohnishi, Hiroaki Okamoto. Direct-acting antiviral agent-resistant mutants in patients with type C chronic liver diseases: Detection and its clinical significanceKanzo 2015; 56(11): 621 doi: 10.2957/kanzo.56.621
17
Qi-Fei Zhong, Rui Liu, Gang Liu. Structure–activity relationship studies on quinoxalin-2(1H)-one derivatives containing thiazol-2-amine against hepatitis C virus leading to the discovery of BH6870Molecular Diversity 2015; 19(4): 829 doi: 10.1007/s11030-015-9610-6
18
Kittirat Glab-ampai, Aijaz Ahmad Malik, Monrat Chulanetra, Jeeraphong Thanongsaksrikul, Kanyarat Thueng-in, Potjanee Srimanote, Pongsri Tongtawe, Wanpen Chaicumpa. Inhibition of HCV replication by humanized-single domain transbodies to NS4BBiochemical and Biophysical Research Communications 2016; 476(4): 654 doi: 10.1016/j.bbrc.2016.05.109
19
Nicasio Mancini, Lara Marrone, Nicola Clementi, Giuseppe A Sautto, Massimo Clementi, Roberto Burioni. Adoptive T-cell therapy in the treatment of viral and opportunistic fungal infectionsFuture Microbiology 2015; 10(4): 665 doi: 10.2217/fmb.14.122
20
Ruben Brandão, Rute Marcelino, Fátima Gonçalves, Isabel Diogo, Ana Carvalho, Joaquim Cabanas, Inês Costa, Pedro Brogueira, Fernando Ventura, Ana Miranda, Kamal Mansinho, Perpétua Gomes. Characterization of NS5A and NS5B Resistance-Associated Substitutions from Genotype 1 Hepatitis C Virus Infected Patients in a Portuguese CohortViruses 2018; 10(5): 223 doi: 10.3390/v10050223
21
Ying Cao, Yu Zhang, Yi Bao, Renwen Zhang, Xiaxia Zhang, Wei Xia, Hao Wu, Xiaoyuan Xu. Naturally occurring hepatitis C virus protease inhibitors resistance-associated mutations among chronic hepatitis C genotype 1b patients with or without HIV co-infectionHepatology Research 2016; 46(6): 552 doi: 10.1111/hepr.12590
22
Jingshu Zhang, Yun Lan, Sumana Sanyal. Modulation of Lipid Droplet Metabolism—A Potential Target for Therapeutic Intervention in Flaviviridae InfectionsFrontiers in Microbiology 2017; 8 doi: 10.3389/fmicb.2017.02286
23
John A. Howe, Jianmin Long, Stuart Black, Robert Chase, Patricia McMonagle, Stephanie Curry, Seth Thompson, Mark J. DiNubile, Anita Y. M. Howe. Clinical Implications of Detectable Baseline Hepatitis C Virus-Genotype 1 NS3/4A-Protease Variants on the Efficacy of Boceprevir Combined With Peginterferon/RibavirinOpen Forum Infectious Diseases 2014; 1(2) doi: 10.1093/ofid/ofu078
24
Rita C.F. Tavares, Ana C.C.A. Feldner, João R.R. Pinho, Silvia N.O. Uehara, Christini T. Emori, Roberto J. Carvalho-Filho, Ivonete S.S. Silva, Rúbia A.F. Santana, Vanessa F.D. de Castro, Gregório T. F. Castoli, Charliana U. Cristovão, Maria L.C.G. Ferraz. Prevalence of naturally occurring protease inhibitor resistance-associated variants in hemodialysis and renal transplant patients with hepatitis C virus infectionEuropean Journal of Gastroenterology & Hepatology 2017; 29(7): 754 doi: 10.1097/MEG.0000000000000866
25
Surasak Jittavisutthikul, Watee Seesuay, Jeeraphong Thanongsaksrikul, Kanyarat Thueng-in, Potjanee Srimanote, Rolf G. Werner, Wanpen Chaicumpa. Human Transbodies to HCV NS3/4A Protease Inhibit Viral Replication and Restore Host Innate ImmunityFrontiers in Immunology 2016; 7 doi: 10.3389/fimmu.2016.00318